Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDO-67: Ki67-guided endocrine therapy window study in breast cancer
2025-521385-10-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Erasmus MC. Primary endpoints: Endoxifen levels after three months of tamoxifen, Tamoxifen resistance by Ki67 at three weeks and 1 more. Planned start Oct 2025; status: authorised.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521385-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521385-10-00.